نتایج جستجو برای: ezh2

تعداد نتایج: 2721  

2015
Laura A. Galvis Aliaksei Z. Holik Kieran M. Short Julie Pasquet Aaron T. L. Lun Marnie E. Blewitt Ian M. Smyth Matthew E. Ritchie Marie-Liesse Asselin-Labat

Epigeneticmechanisms involved in theestablishment of lungepithelial cell lineage identities during development are largely unknown. Here, we explored the role of the histonemethyltransferaseEzh2 during lung lineage determination. Loss of Ezh2 in the lung epithelium leads to defective lung formation and perinatal mortality. We show that Ezh2 is crucial for airway lineage specification and alveol...

2014
Heidi M. Ott Alan P. Graves Melissa B. Pappalardi Michael Huddleston Wendy S. Halsey Ashley M. Hughes Arthur Groy Edward Dul Yong Jiang Yuchen Bai Roland Annan Sharad K. Verma Steven D. Knight Ryan G. Kruger Dashyant Dhanak Benjamin Schwartz Peter J. Tummino Michael T. McCabe

The EZH2 methyltransferase silences gene expression through methylation of histone H3 on lysine 27 (H3K27). Recently, EZH2mutations have been reported at Y641, A677, and A687 in non-Hodgkin lymphoma. Although the Y641F/N/S/H/C and A677G mutations exhibit clearly increased activity with substrates dimethylated at lysine 27 (H3K27me2), the A687Vmutant has been shown to prefer a monomethylated lys...

Journal: :Oncology reports 2012
Ruijian Zhang Ruijun Wang Hong Chang Fei Wu Chuntao Liu Dongfeng Deng Wenhai Fan

The Ezh2 gene is an important member of the polycomb-group (PcG) family. As a newly identified oncogene, the expression of Ezh2 has been shown to be significantly increased in prostate cancer, breast cancer, renal cell carcinoma and hepatic cancer; however, a role for Ezh2 in the occurrence of glioma has not yet been reported. In this study, we fo...

2015
Anthony M. Barsotti Michael Ryskin Wenyan Zhong Wei-Guo Zhang Andreas Giannakou Christine Loreth Veronica Diesl Maximillian Follettie Jonathan Golas Michelle Lee Timothy Nichols Conglin Fan Gang Li Stephen Dann Valeria R. Fantin Kim Arndt Dominique Verhelle Robert A. Rollins

In addition to genetic alterations, cancer cells are characterized by myriad epigenetic changes. EZH2 is a histone methyltransferase that is over-expressed and mutated in cancer. The EZH2 gain-of-function (GOF) mutations first identified in lymphomas have recently been reported in melanoma (~2%) but remain uncharacterized. We expressed multiple EZH2 GOF mutations in the A375 metastatic skin mel...

2017
Yordan Sbirkov Colin Kwok Amandeep Bhamra Andrew J. Thompson Veronica Gil Arthur Zelent Kevin Petrie

Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function and loss-of-function, have been linked to a variety of haematological malignancies and solid tumours, suggesting a complex, context-dependent role of this methyltransferase. The successful implementation of molecularly targeted therapies against EZH2 requires a greater understanding of the poten...

Journal: :Science 2012
Kexin Xu Zhenhua Jeremy Wu Anna C Groner Housheng Hansen He Changmeng Cai Rosina T Lis Xiaoqiu Wu Edward C Stack Massimo Loda Tao Liu Han Xu Laura Cato James E Thornton Richard I Gregory Colm Morrissey Robert L Vessella Rodolfo Montironi Cristina Magi-Galluzzi Philip W Kantoff Steven P Balk X Shirley Liu Myles Brown

Epigenetic regulators represent a promising new class of therapeutic targets for cancer. Enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2), silences gene expression via its histone methyltransferase activity. We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor....

2018
Farnaz Boostani Roya Dolatkhah Ashraf Fakhrjou Faris Farassati Zohreh Sanaat

Background Recently, it was found that the overexpression and mutation status of EZH2 affect cancer progression and patient outcome in several human tumors. We aimed to evaluate the clinicopathologic significance of EZH2 in patients with breast cancer. Methods This was an analytical descriptive study of surgical specimens of primary breast tumors. Specimens were analyzed immunohistochemically...

2017
Thai Huu Ho Payal Kapur Jeanette E. Eckel-Passow Alana Christie Richard W. Joseph Daniel J. Serie John C. Cheville R. Houston Thompson Farrah Homayoun Vandana Panwar James Brugarolas Alexander S. Parker

Purpose Enhancer of zeste homolog 2 (EZH2), a chromatin remodeler, is implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC). However, the effect of EZH2 on outcomes in localized ccRCC is unclear, and molecular biomarkers are not currently integrated into prognostic models or adjuvant therapy trials. Methods We performed Cox regression to evaluate the association of tumor-bas...

2013
Zhaomei Mu Hua Li Sandra V Fernandez Katherine R Alpaugh Rugang Zhang Massimo Cristofanilli

INTRODUCTION Inflammatory breast cancer (IBC) is the most metastatic variant of breast cancer with the poorest survival in all types of breast cancer patients and presently therapeutic targets for IBC are very limited. Enhancer of zeste homolog 2 (EZH2) is frequently expressed in human IBC and its expression positively correlates with worse clinical outcome. However, the molecular basis for EZH...

Journal: :Hypertension 2012
Henryk Dreger Antje Ludwig Andrea Weller Verena Stangl Gert Baumann Silke Meiners Karl Stangl

The histone methyltransferase enhancer of zeste homolog 2 (Ezh2) mediates trimethylation of lysine 27 in histone 3, which acts as a repressive epigenetic mark. Ezh2 is essential for maintaining pluripotency of stem cells, but information on its role in differentiated cells is sparse. Whole-genome mRNA expression arrays identified 964 genes that were regulated by >2-fold 72 hours after small int...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید